N-terminal stretch Arg(2), Arg(3), Arg(4) and Arg(5) of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA

被引:171
作者
vanBerkel, PHC
Geerts, MEJ
vanVeen, HA
Mericskay, M
deBoer, HA
Nuijens, JH
机构
[1] PHARMING BV,NL-2333 CA LEIDEN,NETHERLANDS
[2] LEIDEN UNIV,LEIDEN INST CHEM,MED BIOTECHNOL DEPT,GORLAEUS LABS,NL-2333 CC LEIDEN,NETHERLANDS
关键词
D O I
10.1042/bj3280145
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human lactoferrin (hLF), a protein involved in host defence against infection and excessive inflammation, interacts with heparin, the lipid A moiety of bacterial lipopolysaccharide, human lysozyme (hLZ) and DNA. To determine which region of the molecule is important in these interactions, solid-phase ligand binding assays were performed with hLF from human milk (natural hLF) and N-terminally deleted hLF variants. Iron-saturated and natural hLF bound equally well to heparin, lipid A, hLZ and DNA. Natural hLF lacking the first two N-terminal amino acids (Gly(1)-Arg(2)) showed reactivities of one-half, two-thirds, one-third and one-third towards heparin, lipid A, hLZ and DNA respectively compared with N-terminally intact hLF. A lack of the first three residues (Gly(1)-Arg(2)-Arg(3)) decreased binding to the same ligands to one-eighth, one-quarter, one-twentieth and one-seventeenth respectively. No binding occurred with a mutant lacking the first five residues (Gly(1)-Arg(2)-Arg(3)-Arg(4)-Arg(5)). An anti-hLF monoclonal antibody (El1) that reacts to an N-lobe epitope including Arg(5) completely blocked hLF-ligand interaction. These results show that the N-terminal stretch of four consecutive arginine residues, Arg(2)-Arg(3)-Arg(4)-Arg(5), has a decisive role in the interaction of hLF with heparin, lipid A, hLZ and DNA. The role of limited N-terminal proteolysis of hLF in its anti-infective and anti-inflammatory properties is discussed.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 36 条
[21]   HUMAN LACTOTRANSFERRIN - AMINO-ACID SEQUENCE AND STRUCTURAL COMPARISONS WITH OTHER TRANSFERRINS [J].
METZBOUTIGUE, MH ;
JOLLES, J ;
MAZURIER, J ;
SCHOENTGEN, F ;
LEGRAND, D ;
SPIK, G ;
MONTREUIL, J ;
JOLLES, P .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1984, 145 (03) :659-676
[22]  
MIYAZAWA K, 1991, J IMMUNOL, V146, P723
[23]  
NIUJENS JH, 1996, J MAMMARY GLAND BIOL, V1, P285
[24]  
NUIJENS JH, 1987, IMMUNOLOGY, V61, P387
[25]   INHIBITION OF LACTOFERRIN AND VITRONECTIN BINDING TO STAPHYLOCOCCUS-AUREUS BY HEPARIN [J].
PAULSSON, M ;
LJUNGH, A ;
WADSTROM, T .
CURRENT MICROBIOLOGY, 1994, 29 (02) :113-117
[26]   MOLECULAR-CLONING AND SEQUENCE-ANALYSIS OF BOVINE LACTOTRANSFERRIN [J].
PIERCE, A ;
COLAVIZZA, D ;
BENAISSA, M ;
MAES, P ;
TARTAR, A ;
MONTREUIL, J ;
SPIK, G .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1991, 196 (01) :177-184
[27]   ISOLATION AND CHARACTERIZATION OF SHEEP LACTOFERRIN, AN INHIBITOR OF PLATELET-AGGREGATION AND COMPARISON WITH HUMAN LACTOFERRIN [J].
QIAN, ZY ;
JOLLES, P ;
MIGLIORESAMOUR, D ;
FIAT, AM .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1995, 1243 (01) :25-32
[28]   COMPLETE NUCLEOTIDE-SEQUENCE OF HUMAN MAMMARY-GLAND LACTOFERRIN [J].
REY, MW ;
WOLOSHUK, SL ;
DEBOER, HA ;
PIEPER, FR .
NUCLEIC ACIDS RESEARCH, 1990, 18 (17) :5288-5288
[29]   MODULATION OF NATURAL-KILLER AND LYMPHOKINE-ACTIVATED KILLER-CELL CYTOTOXICITY BY LACTOFERRIN [J].
SHAU, HY ;
KIM, A ;
GOLUB, SH .
JOURNAL OF LEUKOCYTE BIOLOGY, 1992, 51 (04) :343-349
[30]   Heterogeneity in utilization of N-glycosylation sites Asn(624) and Asn(138) in human lactoferrin: A study with glycosylation-site mutants [J].
vanBerkel, PHC ;
vanVeen, HA ;
Geerts, MEJ ;
deBoer, HA ;
Nuijens, JH .
BIOCHEMICAL JOURNAL, 1996, 319 :117-122